COMMUNIQUÉ DE PRESSE

par MEDIAN TECHNOLOGIES (EPA:ALMDT)

Changes in the rights attaching to the classes of shares or securities

image 

Press release – For immediate release September 6, 2024 – 5:45 pm CEST

Disclosure of total number of voting rights and number of shares in the capital as of August 3[1]st, 2024

 

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

 

Sophia Antipolis, France 

 

Total number of shares

18,448,233

Number of real voting rights*                   (excluding treasury shares**)

18,363,983

Theoretical number of voting rights*            (including treasury shares**)

18,425,033

(*) Class E preference shares are non-voting

(**) pursuant to article 223-11 of the AMF’s General Regulations

 

 

imageAbout Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on

the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

Contacts

 

Median Technologies

Emmanuelle Leygues

Head of Corporate Marketing & Financial

Communications

+33 6 10 93 58 88                   

emmanuelle.leygues@mediantechnologies.com  

Press - ALIZE RP

Caroline Carmagnol  +33 6 64 18 99 59 median@alizerp.com    

Investors - ACTIFIN

Ghislaine Gasparetto +33 6 21 10 49 24

ghislaine.gasparetto@seitosei-actifin.com 

 

 



[1] | P a g e

Voir toutes les actualités de MEDIAN TECHNOLOGIES